{
  "id": 7638482,
  "title": "World-first psilocin binge eating disorder trial reveals improvement in all patients",
  "url": "https://urgent.news/2026/09/15/world-first-psilocin-binge-eating-disorder-trial-reveals-improvement",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-15T21:20:07.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-09-world-psilocin-binge-disorder-trial.html"
  },
  "original_language": "en",
  "account": "A world-first clinical trial of IV-infused psilocin for binge-eating disorder has shown remarkable results, with all participants experiencing improvements. After just two treatments, 50% of patients did not experience any binge-eating episodes during the 84-day follow-up period. The pilot trial achieved a 73% reduction in binge-eating episodes for the six patients who were previously treatment-resistant, and also led to significant reductions in anxiety, depression, and an overall 61% improvement in quality of life. Swinburne University of Technology's director of clinical trials, Susan Rossell, expressed delight at maintaining the trial's success at the four-week mark, as these patients had previously struggled with the disorder for up to 20 years and had previously failed treatments. Prior to the study, these patients averaged 2.3 binge-eating episodes per week. Entropy Neurodynamics CEO Jason Carroll emphasized the encouraging nature of the 12-week results, stating that the goal is not to develop a daily medication, but to investigate if a limited number of precision-controlled psychedelic treatments can provide lasting benefits after the treatment has ended. The researchers believe these early data from a small study provide strong clinical validation for continued development of the precision-controlled approach TRP-8803.",
  "summary": "Swinburne University of Technology and Entropy Neurodynamics' world's first IV-infused psilocin binge-eating disorder trial has led to improvements in all participants.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}